Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Codexis to Participate in Upcoming Healthcare Conferences

CDXS

REDWOOD CITY, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that management will participate in four upcoming investor conferences.

The Stifel 2024 Healthcare Conference (New York, NY)

  • Monday, November 18, 2024, at 2:25 pm ET, management will participate in a fireside chat

The Jefferies London Healthcare Conference (London, UK)

  • Tuesday, November 19, 2024, at 9:30 am GMT, management will participate in a fireside chat

The 15th Annual Craig-Hallum Alpha Select Conference (New York, NY)

  • Tuesday, November 19, 2024, management will host 1x1 investor meetings

The Stephens Annual Investment Conference (Nashville, TN)

  • Thursday, November 21, 2024, at 12:00 pm CT, management will participate in a fireside chat

Live webcasts of each fireside chat will be available on the Investor Relations section of the Company’s website, https://ir.codexis.com. A replay of each fireside chat will be archived for 90 days following the presentation date.

About Codexis

Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com.

For More Information

Investor Contact
Carrie McKim
(336) 608-9706
ir@codexis.com

Media Contact
Lauren Musto
(650) 421-8205
media@codexis.com


Primary Logo



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today